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Abstract. Background: Hydantoin derivatives possess a
variety of biochemical and pharmacological properties.
Although hydantoin compounds are studied extensively, there
are not many studies that investigate their anticancer
properties. Materials and Methods: Thirty hydantoin
compounds were evaluated for their efflux modulating effects
in cancer cells using a rhodamine 123 accumulation assay
and real-time fluorometry based on the intracellular
accumulation of ethidium bromide. Results: The 30
derivatives were screened by real-time fluorometry for
rhodamine 123 accumulation. Among the selected
derivatives, compounds SZ-7, LL-9, BS-1, MN-3, P3, RW-
15b, AD-26, RW-13, AD-29 and KF-2 significantly increased
the retention of rhodamine 123. Compounds AD-26, AD-29,
RW-13, KF-2, BS-1, MN-3, RW-15b and JH-63 showed
synergistic effect with doxorubicin on mouse lymphoma cells.
Furthermore, compound SZ-7 had indifferent effect with
doxorubicin. Conclusion: These results indicated the role of
chemical modifications within the hydantoin ring for its
potential inhibition of the ABCB1 transporter. The most
active structures contained aromatic substituents as well as
some tertiary amine fragments.
Multidrug resistance plays a crucial role in the failure of
treatment of infectious diseases and cancer (1). Micro-
organisms have developed various ways to resist the toxic
effects of antibiotics and other drugs (2, 3). One such
mechanism involves the cytoplasmic membrane-localised
transport system, which also takes part in normal
physiological functions (4). In cancer patients, the main reason
for treatment failure is the presence of resistance to the
chemotherapy. The major mechanism of multidrug resistance
is the elevated expression of ATP-dependent drug-efflux
pumps, which reduce the accumulation of the anticancer
agents (5). In many tumour cell lines, multidrug resistance is
often associated with the overexpression of ABC drug-
transporter P-glycoprotein (Pgp), also known as ABCB1 (6).
Hydantoin derivatives possess a variety of biochemical
and pharmacological properties and are used to treat many
human diseases. They possess good anticonvulsant properties
and depending on the nature of substitution on the hydantoin
ring, a wide range of other pharmacological properties,
including fungicidal, herbicidal, antitumour, anti-
inflammatory, anti-HIV, hypolipidemic, antiarrhythmic and
antihypertensive activities (7, 8). Although hydantoin
compounds are studied extensively, there are not many
studies about their anticancer properties. Recently, the
cytotoxic activity of spirohydantoin derivatives was tested in
ovarian and breast cancer cells (9). It has been shown that a
spirohydantoin derivative induces growth inhibition and
apoptosis in leukemic cells (10). Former studies
demonstrated that 5-arylidene-2-thiohydantoins have in vitro
antimycobacterial activity (11).
Materials and Methods
Compounds. Thirty hydantoin derivatives (SZ-2, SZ-7, LL-9, BS-1,
JH-63, MN-3, TD-7k, GG-5k, P3, P7, P10, P11, RW-15b, AD-26,
RW-13, AD-29, KF-2, PDPH-3, Mor-1, KK-XV, Thioam-1, JHF-1,
JHC-2, JHP-1, Fur-2, GL-1, GL-7, GL-14, GL-16, GL-18) were
tested, kindly provided by Dr. Jadwiga Handzlik and Prof. Dr.
Katarzyna Kieć-Kononowicz, Cracow, Poland). The compounds
were dissolved in DMSO.
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Other chemicals used in the study were: doxorubicin
hydrochloride (Wako Pure Chem. Ind., Osaka, Japan), rhodamine
123 (R123; Sigma, St. Louis, MO, USA), verapamil (EGIS
Hungarian Pharmaceutical Company, Budapest, Hungary), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma, St Louis, MO, USA), sodium dodecylsulfate (SDS; Sigma),
dimethyl sulfoxide (DMSO; Sigma) and ethidium bromide (EB;
Sigma, St. Louis, MO, USA). Stock solutions of R123 and
verapamil were prepared in water. All solutions were prepared on
day of assay.
Cell lines. L5178Y mouse T-cell lymphoma cells (ECACC cat. no.
87111908; U.S. FDA, Silver Spring, MD, USA) were transfected
with pHa MDR1/A retrovirus, as described previously (12, 13). The
ABCB1-expressing cell line was selected by culturing the infected
cells with 60 ng/ml of colchicine (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) to maintain the MDR phenotype. L5178 mouse
T-cell lymphoma cells (parental, PAR) and the human ABCB1-gene
transfected sub-line (MDR) were cultured in McCoy’s 5A medium
supplemented with 10% heat-inactivated horse serum, L-glutamine
(Lonza BioWhittaker, Verviers, Belgium) and antibiotics (penicillin,
streptomycin) at 37˚C and in a 5% CO2 atmosphere.
Medium. McCoy’s 5A medium (Lonza BioWhittaker) supplemented
with 10% heat-inactivated horse serum (Sigma-Aldrich Química
SA, Madrid, Spain), L-glutamine (Lonza BioWhittaker) and
antibiotics.
Assay for antiproliferative and cytotoxic effect. The effects of
increasing concentrations of the drugs alone on cell growth were
tested in 96-well flat-bottomed microtitre plates. The compounds
were diluted in a volume of 100 μl medium. Then, 6×103 (for
antiproliferative assay) or 2×104 cells (for cytotoxic assay) in 50
μl of medium, respectively, were added to each well, with the
exception of the medium control wells. The culture plates were
further incubated at 37˚C for 24 and 72 h, respectively; at the end
of the incubation period, 15 μl of MTT (thiazolyl blue tetrazolium
bromide, Sigma) solution (from a 5 mg/ml stock) was added to
each well. After incubation at 37˚C for 4 h, 100 μl of sodium
dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M HCI) was
added to each well and the plates were further incubated at 37˚C
overnight. The cell growth was determined by measuring the
optical density (OD) at 550 nm (ref. 630 nm) with Multiscan EX
ELISA reader (Thermo Labsystems, Cheshire, WA, USA).
Inhibition of the cell growth was determined according to the
formula:
Where ID50 is defined as the inhibitory dose that reduces the growth
of the compound-exposed cells by 50%.
Real-time fluorimetry was performed using a previously
developed semi-automated method (14, 15). Briefly, the cells were
adjusted to a density of 2×106 cells/ml, centrifuged at 2000 × g for
2 min and re-suspended in phosphate-buffered saline (PBS) pH 7.4.
The cell suspension was distributed in 90 μl aliquots into 0.2 ml
tubes. The tested compounds were individually added at different
concentrations (4 and 40 mg/l) in 5 μl volumes of their stock
solutions and the samples incubated for 10 min at 25˚C. Verapamil
was used as a positive control. After this incubation, 5 μl (1 μg/ml
final concentration) of EB (20 μg/ml stock solution) were added to
the samples and the tubes were placed into a Rotor-Gene 3000™
thermocycler with real-time analysis software (Corbett Research,
Sidney, Australia) and the fluorescence monitored on a real-time
basis. The results were evaluated by Rotor-Gene Analysis Software
6.1 (Build 93) provided by Corbett Research. 
Flow cytometry assay for evaluation of a compound on the
retention of rhodamine 123 by MDR in tumour cells. This assay
has been fully described previously (16). Briefly, the cells were
adjusted to a density of 2×106/ml, re-suspended in serum-free
McCoy’s 5A medium and distributed in 0.5 ml aliquots into
Eppendorf centrifuge tubes. 10 μl of test compounds were added
at various concentrations (4 and 40 mg/l), and the samples were
incubated for 10 min at room temperature. Next, 10 μl (5.2 mM
final concentration) of rhodamine 123 was added to the samples
and the cells were incubated for a further 20 min at 37˚C, washed
twice and re-suspended in 0.5 ml phosphate-buffered saline (PBS)
for analysis. The fluorescence uptake of the cell population was
measured with FACStar Plus flow cytometer (Beckton, Dickinson
and Company, Franklin Lakes, NJ, USA). Verapamil was used as
a positive control in the rhodamine 123 exclusion experiments.
The percentage mean fluorescence intensity was calculated for the
treated MDR and parental cell lines as compared to untreated
cells. A fluorescence activity ratio (FAR) was calculated via the
following equation, on the basis of the measured fluorescence
values:
The results presented are obtained from a representative flow
cytometry experiment in which 10,000 individual cells of the
population were evaluated for amount of rhodamine 123 retained
are first presented by the Beckton Dickinson FACStar flow
cytometer as histograms and the data converted to FAR units that
define fluorescence intensity, standard deviation, peak channel in
the total and in the gated populations. 
Checkerboard microplate method. The checkerboard microplate
method was applied to study the drug interactions between
resistance modifiers and anticancer drugs on cancer cells, as
previously described (17). The interaction of the anticancer drug
doxorubicin and the resistance modifiers hydantoins was studied in
combination on MDR mouse T-lymphoma cells. The serial dilutions
of doxorubicin (A) were made in 100 μl, horizontally, furthermore
the dilutions of hydantoin derivatives (B) vertically, in 50 μl volume
in the microtiter plate (the dilutions were prepared separately in
Eppendorf tubes, using tissue culture medium). An aliquot of 50 μl
of the cell suspension in tissue culture medium containing 2×104
cells was distributed to each well and the plates incubated for 48 h
at 37˚C in a CO2 incubator. The cell growth rate was determined
after MTT staining and the intensity of the blue colour was
measured with micro ELISA reader. Drug interactions were
evaluated according to the following protocol, where ID50 is defined
as the inhibitory dose that reduces the growth of the compound-
exposed cells by 50%. 
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ID50=50% inhibitory dose. 
FIC=fractional inhibitory concentration
FIX=fractional inhibitory index
FICA=ID50A in combination/ID50A alone







After determination of ID50 values of the hydantoin
derivatives in antiproliferative and cytotoxicity assays, all of
the compounds at varying concentrations were evaluated for
effects on the real-time accumulation of EB by human
MDR1 (ABCB1) gene transfected mouse lymphoma cells.
Using this method (15, 18), a large number of compounds
can be screened and selected for further studies. Because of
the extremely large number of graphs that result from the
evaluation of each compound at two concentrations, Figure 1
serves as an example of the type of data that results from the
assay and which afforded the selection of compounds that
presented with significant activity. The following compounds
at concentrations that were not toxic (Table I) were selected
for rhodamine 123 accumulation studies: SZ-2, SZ-7, LL-9,
BS-1, JH-63, MN-3, GG-5k, P3, RW-15b, AD-26, RW-13,
AD-29, KF-2, PDPH-3 and KK-XV. The inhibition of
ABCB1 transporter is evident when FAR >1. As
demonstrated by Table II, the compounds SZ-7, LL-9, BS-1,
MN-3, P3, RW-15b, AD-26, RW-13, AD-29 and KF-2,
significantly increase retention of rhodamine 123. Compound
BS-1 was the most potent inhibitor in as much as very low
concentrations produced the greatest retention of the
fluorescent substrate. 
From the most effective compounds presenting high FAR
values, nine compounds were chosen to determine their
interaction with the anticancer drug doxorubicin. Compounds
AD-26, AD-29, RW–13, KF-2, BS-1, MN-3, RW-15b, JH-63
and SZ-7 were combined with doxorubicin using MDR1
(ABCB1) gene transfected mouse lymphoma cells.
Compounds AD-26, AD-29, RW–13, KF-2, BS-1, MN-3,
RW-15b and JH-63 showed synergistic effect with
doxorubicin on mouse lymphoma cells; compound SZ-7 had
an indifferent effect with doxorubicin (Table III).
Discussion
Various aspects of the biochemical and pharmacological
properties of hydantoin derivatives have been studied (7, 8, 11).
However, the anticancer activity of these compounds has
received little attention. Among those few studies, two novel
spirohydanto in compounds, 8-(3,4-difluorobenzyl)-1’-(pent-4-
enyl)-8-azaspiro[bicyclo[3.2.1] octane-3,4’-imidazolidine]-
2’,5’-dione (DFH) and 8-(3,4-dichlorobenzyl)-1’-(pent-4-enyl)-
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Figure 1. Accumulation of EB (1 mg/l) by human MDR1 (ABCB1) gene-transfected mouse lymphoma cells in the presence of 4 and 40 μg/ml of
AD-29.
8-azaspiro[bicyclo[3.2.1]octane-3,4’-imidazolidine]-2’,5’-dione
(DCH) produce dose- and time-dependent cytotoxic effects on
human leukemic, K562, Reh, CEM and 8E5 cell lines and
induce apoptosis. This has previously been further confirmed
and quantified both by fluorescence-activated cell sorting
(FACS) and confocal microscopy following annexin V-
FITC/propidium iodide staining (10). Furthermore, naturally-
occurring or synthetic phenyl-methylene hydantoin (PMH) and
S-ethyl PMH (S-PMH) reportedly augment cell–cell adherence
and reduce invasion and growth of prostate cancer cells (19). 
The mouse lymphoma cell line transfected with the human
MDR1 gene that codes for the ABC transporter Pgp that is
responsible for multidrug resistance of this cell line to
cytotoxic agents is a very useful model for evaluating agents
that inhibit the activity of the transporter. Among the
hydantoin derivatives evaluated for potential inhibition of the
P-gp1 transporter, BS-1, MN-3 and JH-63 at the lowest
concentration of 4 mg/l, were the most effective inhibitors.
All of the most active structures contained aromatic
substituents as well as some tertiary amine fragments.
Based on the results obtained, compounds AD-26, AD-29,
RW-13, KF-2, BS-1, MN-3, RW-15b and JH-63 should be
further studied for in vitro capability of reversing or reducing
ANTICANCER RESEARCH 30: 4867-4872 (2010)
4870
Table I. Antiproliferative and cytotoxic effects of hydantoin derivatives
on multidrug resistant (MDR) human MDR1 (ABCB1) gene-transfected
mouse lymphoma cells. The non-toxic compounds used for further
studies are in grey. 
ID50 (μg/ml)
Hydantoin Cytotoxic Antiproliferative Precipitation 
derivative effect effect (crystal type)
GG-5k 151.23 72.66 -
P7 18.15 87.13 Oval
P10 286.50 112.09 Pine-leaf-like
P11 115.71 118.77 -
Mor-1 240.24 76.80 -
JHF-1 225.71 111.59 -
JHC-2 143.80 84.78 -
JHP-1* N.D. N.D. -
Fur-2 426.01 94.64 -
GL-7 313.42 47.34 -
GL-14 276.72 78.78 -
GL-16 208.35 100.99 -
DMSO 2.39% 1.09% -
*Complex formation with MTT in McCoy’s 5A medium, ID50 non-
determinable.
Table II. Effect of compounds SZ-2, SZ-7, LL-9, BS-1, JH-63, MN-3,
TD-7k, GG-5k and P3 on rhodamine 123 retention by human MDR1
(ABCB1) gene-transfected mouse lymphoma cells. The most promising






























FAR: Fluorescence activity ratio.
resistance of the mouse lymphoma MDR1 (ABCB1) gene
transfected cell to cytotoxic agents to which they are initially
resistant. Active compounds should then be examined in the
mouse model for ability to shrink solid transplanted tumours
in order to assess their suitability to progress to clinical trial. 
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Table III. Interaction between selected hydantoin derivatives and
doxorubicin on MDR1 (ABCB1)-gene transfected mouse lymphoma
cells. 
Compound FIX values Interaction
AD-26 0.032 Synergism
AD-29 0.076 Synergism
RW-13 0.16 Synergism
KF-2 0.18 Synergism
BS-1 0.217 Synergism
MN-3 0.311 Synergism
RW-15b 0.24 Synergism
JH-63 0.493 Synergism
SZ-7 1.252 Indifferent
